Clinical Trial Update: Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Larotaxel with continuous 5-FU in advanced pancreatic cancer previously treated with gemcitabine; trial status completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Larotaxel (larotaxel)

Snippet

Sponsor: Sanofi | Conditions: Pancreatic Neoplasms | Phase 3 | Status: COMPLETED